Head-to-head · Cost-Efficiency Index
Prime Health vs Kin Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Prime Health
Shoppers who want dead-simple, flat, no-dose-escalation pricing and don't need to see LegitScript or a named medical director before signing up.
Visit Prime HealthKin Meds
Shoppers modeling the real monthly cost before they commit.
Visit Kin MedsThe verdict
Prime Health takes it, leading the Cost-Efficiency Index 48 to 47. Prime Health Weight Management is a nurse-practitioner-led telehealth service offering compounded semaglutide and tirzepatide at simple, flat monthly rates that don't increase as the dose is titrated up. Kin Meds still earns a C — Shoppers modeling the real monthly cost before they commit.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Prime Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Prime Health | Kin Meds |
|---|---|---|
| Cost-Efficiency Index | 48/100 | 47/100 |
| Semaglutide / mo | $299/mo (all doses, compounded) | Not disclosed |
| Tirzepatide / mo | $399/mo (all doses, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $3,588 | — |
| Tirzepatide / yr (modeled) | $4,788 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #442 | #447 |
Prime Health
48/100Where the value is
- Flat pricing that doesn't rise as your dose increases
- Both compounded semaglutide and tirzepatide offered
- 10% weight-loss money-back guarantee
The tradeoffs
- No medical director named anywhere on the site
- No compounding pharmacy partner disclosed
Kin Meds
47/100Where the value is
- Appears to have an established web/social presence per search results
The tradeoffs
- Site is unreachable for independent verification behind active bot/CAPTCHA protection
- No pricing, medical director, or pharmacy partner could be confirmed directly from the company
Regulatory note: the FDA issued a warning letter to Kin Meds in February 2026. We still list and link to Kin Meds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.